GLPwatch

Nutrient-Stimulating Hormone-Based Therapies for Obesity.

Endocrinol Metab Clin North Am · 2025

Last updated 2026-05-28

A new class of medications called nutrient-stimulating hormone (NuSH) therapies, including liraglutide, semaglutide, and tirzepatide, has been shown to be effective for long-term weight management in people with obesity. These FDA-approved drugs work by targeting hormones involved in appetite and energy regulation.

AI summary of the abstract below.

JournalEndocrinol Metab Clin North Am, 2025
Citations4
Molecules
Conditions studied Obesity

Abstract

Obesity is a chronic disease with an increasing worldwide prevalence. Improving obesity is of paramount importance given its association with conditions such as type 2 diabetes, cardiovascular disease, and cancer among others. In the last decade, a new class of highly efficacious medications called nutrient-stimulating hormone (NuSH) therapies has emerged. This article highlights the effectiveness of the FDA-approved NuSH-based therapies-liraglutide, semaglutide, and tirzepatide-in long-term weight management. Ongoing trials are exploring novel mechanisms of action to simultaneously target multiple receptors involved in appetite and energy regulation, promising further advancements and additional treatment options in the field of obesity management.

Verbatim abstract via PubMed 39919868 ↗